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Abstract
In this paper we introduce a single serotype transmission model, including an age-
dependent mosquito biting rate, to find the optimal vaccination age against dengue in
Brazil with Dengvaxia. The optimal vaccination age and minimal lifetime expected
risk of hospitalisation are found by adapting a method due to Hethcote (Math Biosci
89:29–52). Any number and combination of the four dengue serotypes DENv1–
4 is considered. Successful vaccination against a serotype corresponds to a silent
infection. The effects of antibody-dependent enhancement (ADE) and permanent
cross-immunity after two heterologous infections are studied. ADE is assumed to
imply risk-free primary infections, while permanent cross-immunity implies risk-free
tertiary and quaternary infections. Data from trials of Dengvaxia indicate vaccine effi-
cacy to be age and serostatus dependent and vaccination of seronegative individuals to
induce an increased risk of hospitalisation. Some of the scenarios are therefore recon-
sidered taking these findings into account. The optimal vaccination age is compared to
that achievable under the current age restriction of the vaccine. If vaccination is not con-
sidered to induce risk, optimal vaccination ages are very low. The assumption of ADE
generally leads to a higher optimal vaccination age in this case. For a single serotype
vaccination is not recommended in the case of ADE. Permanent cross-immunity results
in a slightly lower optimal vaccination age. If vaccination induces a risk, the optimal
vaccination ages are much higher, particularly for permanent cross-immunity. ADE
has no effect on the optimal vaccination age when permanent cross-immunity is con-
sidered; otherwise, it leads to a slight increase in optimal vaccination age.
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1 Introduction
Dengue is considered the most important mosquito-borne viral disease of humans
with half of the world’s population living in endemic areas and over 2 million dengue
cases reported each year to the World Health Organization (2009, 2012). Due to the
occurrence of asymptomatic infections and atypical clinical presentation dengue is in
fact significantly under-reported so that the actual annual incidence is much higher
(Gubler 2011); it has recently been estimated to be as high as 390 million cases of which
approximately 100 million are symptomatic (Bhatt et al. 2013). These symptomatic
cases of dengue fever (DF) are usually characterised by high fever accompanied by
fatigue, rash, and headaches. If the disease manifests in one of its severe forms, i.e.
dengue haemorrhagic fever (DHF) or dengue shock syndrome (DSS), symptoms can
be plasma leakage and organ failure which can lead to death (Halstead 1980; Fredericks
and Fernandez-Sesma 2014).
There are four distinct dengue virus serotypes DENv1–4 all of which are mainly
spread by the Aedes Aegypti mosquito in Brazil and can cause any manifestation of
dengue from an asymptomatic infection to severe dengue (SD). The coexistence of four
serotypes entails the possibility of consecutive, heterologous infections which may be
affected by interactions between serotypes and antibodies that were developed upon
exposure to the different types. In fact, it is thought that a primary infection with any
serotype leads to lifelong immunity specific to that type but protection against the other
serotypes for a limited time only (Halstead 1980). Some studies have further shown that
secondary infections cause 90–95% of cases of SD, with the remaining 5–10% being
caused by primary infections, usually in infants between the ages of 6 and 12 months
who have a low level of maternal antibodies (Leong et al. 2007; Halstead 2009; Jain and
Chaturvedi 2010). Therefore, a consequence of the coexistence of several serotypes
seems to be the enhancement of infection, particularly during secondary infections and
during primary infections in infancy when maternal antibodies fall to low levels. This
increase in infection severity is believed to be caused by a higher virulence which is in
turn due to antibodies specific to the first serotype an individual was infected with or
those passed on by the mother. These antibodies are cross-reactive with heterologous
dengue types but non-neutralising and thus cause antibody-dependent enhancement
(ADE) by binding on to the very similar dengue serotype and allowing the active virus
entry into its target cells more easily (Halstead 2009; Jain and Chaturvedi 2010). Other
observations regarding heterologous infections are that the sequence of serotypes with
which individuals get infected influences the development of SD (Fried et al. 2010)
and that two heterologous infections confer permanent cross-immunity (Gibbons et al.
2007; Anderson et al. 2013). Considering all of these complex interdependencies it is
not surprising that instead of vaccines mainly vector control strategies were used to
prevent the transmission of dengue in the past.
The development of a dengue vaccine was a complicated and lengthy process;
however, in December 2015 after 20 years of development Sanofi Pasteur licensed
Dengvaxia, the first vaccine against dengue (Sanofi Pasteur Press Release 2015). Since
then it has been licensed for the use in individuals between the ages of either 9 and 45 or
9 and 60 years in more than ten countries including Brazil (Sanofi Pasteur Press Release
2016). Even before the licensure of Dengvaxia mathematical models had been used
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to predict the impact vaccination could have on the spread of dengue, and considering
the complicated interdependencies like ADE and short-term cross-protection there
is unsurprisingly some dispute about the effects of vaccination. While there is an
overall agreement that vaccination could reduce DF cases significantly (Coudeville and
Garnett 2012; Knipl and Moghadas 2015), there are indications that vaccination in the
presence of ADE could lead to more SD cases (Knipl and Moghadas 2015). Ferguson
et al. (2016) draw the conclusion that the transmission setting plays an important role
in whether dengue vaccine will be beneficial or harmful by making the assumption that
vaccination acts as a silent natural infection and by using a mathematical transmission
model to show that in low-transmission settings vaccination may lead to more SD
cases, whereas in high-transmission settings vaccination will be favourable both for
the population as a whole and for the vaccinated individual. It can therefore be said
that the phenomenon of ADE in dengue infections poses a great challenge for the
development of vaccines since it makes it necessary to achieve a successful immune
response to all four serotypes in order to prevent the creation of enhancing antibodies
(Stephenson 2005). Dengvaxia, the only available vaccine at the moment, has been
shown to be at least partially effective against all dengue serotypes in several Phase III
trials; however, it has been found to have different efficacies for each of the serotypes
and these efficacies further seem to depend on the age at vaccination and the serostatus
of the vaccine recipient (Capeding et al. 2014; Hadinegoro et al. 2015). Since the
licensing of Dengvaxia concerns about its application have been raised; in particular
its use in seronegative recipients has been questioned since in this group an increase in
the risk of acquiring SD in a subsequent natural infection has been observed (Aguiar
et al. 2016; Halstead and Russell 2016; SAGE/World Health Organization 2016). This
observation seems to be in agreement with the findings of Ferguson et al. (2016)
pointing towards vaccination causing ADE in the first natural infection if seronegative
individuals are vaccinated.
While recently much attention has been given to the possible effects of vaccination
and to the optimisation of vaccination strategies in order to employ the most cost-
effective strategy of vaccination or to achieve herd immunity and eradication of the
disease (Billings et al. 2008; Durham et al. 2013) the age at which vaccination should
ideally take place has rarely been considered. However, mathematical modelling has in
the past been used to find optimal vaccination ages for other infectious diseases such
as rubella and measles (Hethcote 1988; Anderson and May 1983) and we employ
a method due to Hethcote (1988) to do the same for dengue. The existence of four
dengue serotypes requires us to extend this method to take account of any number of
serotypes existing in one endemic area, and we further take account of the survival
probability of humans which Hethcote (1988) neglected. Additionally, while in many
dengue transmission models the mosquito biting rate and the human mortality rate
are assumed constant, we want to model more realistic transmission dynamics by
assuming an age-dependent mosquito biting rate and a step death function which is
more realistic for countries like Brazil. In this paper our objective is therefore to find
optimal vaccination ages for dengue when the aim of vaccination is to reduce the risk
of hospitalisation due to SD. While considering a single serotype transmission model
to achieve this we still take account of the possible coexistence of multiple serotypes
in an endemic area and the assumptions relating to their interactions by utilising a risk
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function to incorporate them into the model. Additionally, we investigate the optimal
vaccination age when vaccination of seronegative individuals can have negative effects.
2 VaccinationModel
In order to find optimal vaccination ages for dengue we model the transmission of the
virus in the presence of vaccination. To do this we assume independent transmission of
the four distinct dengue serotypes which allows us to use a single serotype transmission
model where some of the parameters are interchangeable to describe any one of the
serotypes. Considering observations regarding interactions between the serotypes such
as short-term cross-immunity and ADE this is only an approximation of the real
dynamics. However, since these interactions are observed only in the short term the
model can be considered to be a reasonable approximation. We further incorporate
a three-dose vaccination strategy based on the restrictions under which Dengvaxia is
licensed in Brazil by requiring a set of matching conditions to be met in addition to
the initial conditions of the transmission model. These matching conditions include
parameters that are serotype specific to allow for different vaccine efficacies for each
serotype and at different vaccination ages.
2.1 Single Serotype TransmissionModel
The Ross–MacDonald model is a common way to describe vector-borne infections
such as dengue (Esteva and Vargas 1998; Garba et al. 2008), and the model we use is
in fact of this type with the relevant modification of considering age density functions
rather than total numbers for the human population.
We assume that humans potentially progress through four different stages in their
life. Every human is born passively immune due to maternal antibodies, once these
antibodies decline the individual becomes susceptible to the virus so that an adequate
contact with the virus leads to infection with dengue from which an individual even-
tually recovers. Once humans recover they are immune to the serotype that they were
infected with for the remainder of their life. By taking the loss of passive immunity
to be given by an age-dependent function C(a) which is estimated for each of the
four dengue serotypes individually using data on the decline of maternal antibod-
ies given by van Panhuis et al. (2011) and by taking the death rate to be the same
for both passively immune and susceptible individuals we can in fact consider one
compartment of unaffected which comprises both the passively immune and the sus-
ceptible. Therefore, the age densities UH (a, t), IH (a, t), and RH (a, t) of ‘unaffected’,
‘infected’, and ‘recovered’ humans at time t are modelled. The age densities for pas-
sively immune and susceptible individuals are then given by (1 − C(a))UH (a, t) and
C(a)UH (a, t), respectively, and the age density for the entire human population is
NH (a, t) = UH (a, t) + IH (a, t) + RH (a, t).
As an approximation we consider the total population size NH = NH (t) =∫ ∞
0 NH (a, t)da to be constant over time. The death rate for all compartments is
given by a step death function, i.e. we assume that all humans die at age L . The
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age-dependent natural mortality rate μH (a) and the survival probability π(a) for the
human population are therefore given by
μH (a) =
{
0, 0 ≤ a < L
∞, L ≤ a < ∞, (1)
π(a) =
{
1, 0 ≤ a < L
0, L ≤ a < ∞. (2)
These assumptions lead to the step function equilibrium human age distribution
N (a) = N (a, t) = NH
L
π(a). (3)
Note that a step death function is a more realistic representation than a constant death
rate which is commonly used in these types of models. We shall take the death rate to
be the same in all compartments corresponding to the assumption that dengue does not
cause any additional deaths. This is reasonable since only 25,000 deaths are caused by
dengue out of 390 million infections annually (Bhatt et al. 2013; Gibbons and Vaughn
2002). For the progression from unaffected to infected we assume that humans are
bitten by mosquitoes at a rate q(a) depending on their age according to mosquito
biting data (Massad 2015). Further if a susceptible human is bitten by an infectious
mosquito, the probability of the human becoming infected with dengue is denoted
by b. Using these parameters and functions, and noting that the number of infectious
mosquitoes is denoted by IM (t), the force of infection for the human population is
λH (a, t) = bq(a)IM (t) 1NH . (4)
Once an individual is infected they recover from dengue at a constant rate γH , and
once recovered stay immune until they die. The set of differential equations for the
human population is therefore given by Eq. (6).
For the mosquito population we allow progression through three compartments,
with all mosquitoes being born susceptible. Susceptible mosquitoes become exposed
upon an adequate contact with dengue and infectious after a latency period τ . Infectious
mosquitoes do not recover from dengue but leave the compartment only once they die.
The larval stage is omitted in this model since we are interested in the vaccination
age of humans, so that new mosquitoes are directly recruited into the susceptible
compartment at a constant rate μM . Exposure to the virus, i.e. a susceptible mosquito
biting an infected human, causes transmission of the virus with probability c. We
have already noted that an age-dependent biting rate q(a) is assumed and that the age
density of infected humans is given by IH (a, t) so that adequate contacts take place
at a rate
∫ ∞
0 q(a)IH (a, t)
1
NH da and the force of infection in the mosquito population
is
λM (t) = c
∫ ∞
0
q(a)
IH (a, t)
NH
da. (5)
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The size of the mosquito population NM is assumed constant, and the death rate for
all mosquitoes is given by μM independent of the compartment they are in. For the
mosquito population the set of differential equations is then given by Eq. (7).
The single serotype transmission model with a step death function for the human
population and an age-dependent biting rate is
∂UH
∂a
+ ∂UH
∂t
= −λH (a, t)C(a)UH (a, t) − μH (a)UH (a, t),
∂ IH
∂a
+ ∂ IH
∂t
= λH (a, t)C(a)UH (a, t) − (μH (a) + γH )IH (a, t),
∂ RH
∂a
+ ∂ RH
∂t
= γH IH (a, t) − μH (a)RH (a, t),
∂ NH
∂a
+ ∂ NH
∂t
= −μH (a)NH (a, t),
NH (a, t) = UH (a, t) + IH (a, t) + RH (a, t), (6)
dSM
dt
= −λM (t)SM (t) − μM SM (t) + μM NM ,
dL M
dt
= λM (t)SM (t) − e−μM τ λM (t − τ)SM (t − τ) − μM L M (t),
dIM
dt
= e−μM τ λM (t − τ)SM (t − τ) − μM IM (t),
NM (t) = SM (t) + L M (t) + IM (t), (7)
where the initial conditions are given by
UH (a, 0) = UH ,0(a), IH (a, t) = IH ,0(a) for τ ∈ [−τ, 0], RH (a, 0) = RH ,0(a),
UH (0, t) = NHL , IH (0, t) = 0, RH (0, t) = 0,
for the human population, and by
SM (t) = SM,0 for τ ∈ [−τ, 0], L M (0) = L M,0, IM (0) = IM,0,
for the mosquito population, and the parameters and age-dependent functions that are
used are summarised in Table 1.
2.2 Vaccination Strategy
So far the model described in Eqs. (6) and (7) does not include any vaccination one
way of incorporating a vaccination strategy in the model is to add matching conditions
for each vaccination dose. Using the function C(a) as the seroconversion rate as was
done by Hethcote (1988) and assuming a fraction Vi of the population is vaccinated at
age Ai the probability of becoming immune due to vaccination at age Ai is given by
Vi C(Ai ). Consequently this means the probability of staying unaffected at age Ai is
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Table 1 Description parameters and age-dependent rates used in the model
Parameter Significance
q(a) Total rate per unit time at which a single mosquito bites humans of age a
given by Eq. (11)
b Probability per bite that an initially susceptible human bitten by an infected
mosquito becomes infected
c Probability per bite that an initially susceptible mosquito biting an infected
human becomes infected
NH Total number of humans
L Expected lifetime of humans in Brazil
μH (a) Step death rate depending on L
γH Per capita recovery rate of humans
NM Total number of mosquitoes
μM Natural per capita death rate of mosquitoes
τ Incubation period in mosquitoes (the extrinsic incubation period)
Ai (i = 1, 2, 3) Vaccination age for each of the three vaccination stages
Vi (i = 1, 2, 3) Vaccinated proportion of the population for each vaccination age
1 − Vi C(Ai ) so that there is a jump decrease in the age density of susceptible humans
which leads to the matching condition
lim
a→A+i
UH (a, t) = (1 − Vi C(Ai )) lim
a→A−i
UH (a, t) (8)
for each vaccination dose i . Note that the vaccinated fraction Vi can be utilised to
incorporate the vaccine efficacy.
Combining the single serotype transmission model with the matching conditions
obtained by including vaccination it is now possible to model each of the four dengue
serotypes. The variation in the serotypes can be modelled by using different serocon-
version rates C(a), as well as by substituting different values for the vaccine efficacy
and therefore different fractions Vi . Note that successful vaccination against a serotype
is essentially a silent infection with that serotype.
3 Basic Reproduction Number R0
The basic reproduction number R0 is considered to be one of the most important quan-
tities in epidemiology and is defined as the number of secondary infections produced
from a single infected individual in a naive population, i.e. an entirely susceptible
population (Diekmann et al. 1990). It is therefore possible to obtain R0 for the trans-
mission model described in Eqs. (6) and (7) intuitively. The basic reproduction number
for our model is given by
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R0 = mbce
−μM τ
μM
1
L
∫ ∞
0
q(a)C(a)
∫ ∞
a
q(s)e−γH (s−a)π(s)dsda (9)
where m = NM/NH is the ratio of the number of mosquitoes to humans as outlined
in Supplementary Appendix A.1.
Since our aim is to consider the coexistence of several serotypes we require values
of R0 specific to each of the serotypes. In the literature there is a wide range of
parameter values assumed for general dengue models (Feng and Velasco-Hernández
1997; Coutinho et al. 2006) that could be used to compute R0 as given in Eq. (9).
Instead of determining all parameters for each of the serotypes we want to estimate
serotype-specific R0 from the initial phase of an outbreak as has been done for dengue
before (Massad et al. 2010, 2001; Favier et al. 2006). This is a more robust method as
it does not depend on estimating a large number of parameters. In order to do this an
approximation of the basic reproduction number needs to be obtained by linearising
the model equations and expressing R0 in terms of λ the initial growth rate of an
infection. The approximate expression
R0 ≈ λ + μM
μM
eλτ
∫ ∞
0 q(a)C(a)
∫ ∞
a
q(s)e−γH (s−a)π(s)dsda
∫ ∞
0 q(a)C(a)
∫ ∞
a q(s)e−(λ+γH )(s−a)π(s)dsda
(10)
can be found for the basic reproduction number as outlined in Supplementary Appendix
A.2.
We assume that the rate at which mosquitoes bite humans of a certain age does not
depend on the specific serotype and based on fitting mosquito biting data from Brazil
to a function q(a) = k1ae−k2a , as shown in Fig. 1, is given by
q(a) = 282.7ae−0.08593a (11)
where a is given in years. With this biting rate, the survival probability π(a) as given
in Eq. (2), and by setting C(a) ≡ 1 as an approximation the double integrals in both
expressions of R0 can be solved analytically. For Eqs. (9) and (10) one obtains
R0 ≈ mbce
−μM τ
μM L
k21
(
4k32ω0 + (k2 − γH )2
[
(k2 + γH ) ω1 + k2ω2
])
4k32 (k2 + γH )2 (k2 − γH )2
, (12)
and
R0 ≈ eλτ
(μM + λ) (k2 + γH + λ)2 (k2 − γH − λ)2
(
4k32ω0 + (k2 − γH )2
[
(k2 + γH ) ω1 + k2ω2
])
μM (k2 + γH )2 (k2 − γH )2
(
4k32ω3 − (k2 + γH + λ)2
[
(k2 − γH − λ) ω1 + k2ω2
]) ,
(13)
respectively, where
ω0 =
(
(k2L + 1)2 − γ 2H L2
)
e−2k2 L − ((k2 + γH ) L + 1) e−(k2+γH )L ,
ω1 = 1 − ((k2L + 1) 2k2L + 1) e−2k2 L ,
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Fig. 1 Biting rate data (Massad 2015) where bites per night are recorded for individuals aged 0–56 years
(dots) together with the fitted age-dependent biting rate of the form q(a) = k1ae−k2a (line)
ω2 = 1 − (2k2L + 1) e−2k2 L , and
ω3 = 1 − ((k2 + γH + λ) L + 1) e−(k2+γH +λ)L . (14)
Note that since γH L is the average human lifetime divided by the average infectious
period and therefore very large, γH  k2, λ terms including e−γH L can be neglected
so that ω0 ≈ ((k2L + 1)2 − γ 2H L2)e−2k2 L , and ω3 ≈ 1.
3.1 Serotype-Specific Basic Reproduction Numbers
The basic reproduction number for each serotype DENv1–4 can now be approximated
using Eq. (13). Values for the model parametersγH = 0.14 day−1,μM = 0.025 day−1,
and L = 73.8 years can be found in the literature (Massad et al. 2010; United States
Central Intelligence Agency 2016) and are assumed non-specific for the different
serotypes. k2 = 0.08593 year−1 was found from data as mentioned before and is also
assumed equal for all four serotypes. The initial growth rate λ on the other hand is
serotype specific and can be found for each serotype at the beginning of an epidemic
by fitting the number of new cases of that type to an exponential curve (Massad et al.
2010; Favier et al. 2006).
The Brazilian Ministry of Health (SINAN) recorded the number of dengue cases
by serotype in the years from 2000 to 2014 for the regions North, Northeast, South,
Southeast, and Centre West. To obtain a serotype-specific λ and hence R0 we deter-
mined the first 12 weeks of each epidemic caused by a given serotype for the whole of
Brazil. The corresponding data for each of the regions were then used to find upper and
lower bounds for λ and R0. During the surveyed period DENv1–3 each caused four
major nationwide outbreaks, while DENv4 only caused two. The serotype-specific
reproduction numbers are taken to be the mean of the basic reproduction numbers of
all outbreaks caused by that type and are given alongside their upper and lower bounds
in Table 2 where the upper and lower bounds are the highest and lowest R0 values
obtained for that serotype in any region. While these results seem to be in agreement
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Table 2 Serotype-specific basic
reproduction numbers Serotype R0 Lower bound Upper bound
DENv1 4.7045 1.2230 6.1777
DENv2 2.9942 1.3745 8.5133
DENv3 4.2974 1.4341 13.4129
DENv4 4.1864 1.8291 4.8711
with previous serotype-specific estimates (Coudeville and Garnett 2012; Reiner et al.
2014) it is important to note that there is a significant dependence on which weeks
are considered to correspond to the outbreak. This is due to the fact that the initial
outbreak of an epidemic cannot be ascertained beyond doubt from the data due to
slight differences in the starting point of epidemics caused by the different climatic
conditions in each region.
4 Risk of Infection
Our goal is to apply the transmission model to find optimal vaccination ages. To do this
we need to identify which consequences of an infection vaccination aim to minimise.
This can be achieved by defining the lifetime expected risk of dengue, i.e. the total
risk from infection during the lifetime of an individual by considering the expected
risk from infection with any one serotype.
4.1 Expected Risk from Infection with Serotype i at Age a
To define the expected risk we assume that the transmission dynamics have reached
a steady state. The steady-state force of infection is then λ(a) = limt→∞ λH (a, t),
while the steady-state age distribution of unaffected humans is given by U (a) =
limt→∞ UH (a, t). The probability of being unaffected at age a which is denoted by
u(a) can therefore be obtained by taking the fraction of unaffected with respect to all
humans of age a, i.e. u(a) = U (a)/N (a), where N (a) = NHL π(a) is the equilibrium
density with respect to age of the human population. By considering the matching
conditions the fraction of successfully vaccinated individuals v(a) can be obtained as
v(a) =
⎧
⎪⎪⎪⎨
⎪⎪⎪⎩
0, 0 ≤ a ≤ A1,
q1u(A−1 ), A1 < a ≤ A2,
q1u(A−1 ) + q2u(A−2 ), A2 < a ≤ A3,
q1u(A−1 ) + q2u(A−2 ) + q3u(A−3 ), A3 < a < ∞,
(15)
where qi = Vi C(Ai ) is the probability of becoming immune due to vaccination at
age Ai for i = 1, 2, 3. Consequently 1 − (u(a) + v(a)) is the probability of having
been infected before reaching age a. We further obtain the fraction of unaffected who
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become infected on exposure to be C(a)u(a) and therefore the probability of infection
at age a as P(a) = λ(a)C(a)u(a).
If there is some risk R(a) assigned to being infected at age a that describes how
undesirable an infection at that age is we can obtain the expected risk from an infection
at age a as
E(a) = P(a)R(a) = λ(a)C(a)u(a)R(a). (16)
Note that there are several dengue serotypes so that an infection at age a might be a pri-
mary, secondary, tertiary, or quaternary infection depending on how many serotypes
coexist in an endemic region and whether the infected individual was previously
infected by or vaccinated against any of them. If the risk of each of these types of
infection was the same the expected risk at age a could be described by Eq. (16).
However, since there is substantial evidence that secondary infections cause more
severe infections and some indication that the sequence of serotypes plays an impor-
tant role (Halstead 2009; Fried et al. 2010; Gibbons et al. 2007) the expected risk at age
a depends on how many and which serotypes an individual was previously infected
with. Additionally it has been observed that the risk varies depending on the serostatus
of a vaccine recipient (SAGE/World Health Organization 2016). We therefore need to
find the probabilities of an infection with a given serotype being a primary, secondary,
tertiary, or quaternary infection when previous exposure was caused by natural infec-
tion or vaccination. Note that vaccination is considered to be a silent infection. These
probabilities are calculated as
Pi jkl(a) = λi (a)Ci (a)ui (a)(1 − (u j (a) + v j (a)))(1 − (uk(a)
+ vk(a)))(1 − (ul(a) + vl(a))),
Pi jkl¯(a) = λi (a)Ci (a)ui (a)(1 − (u j (a) + v j (a)))(1 − (uk(a) + vk(a)))ul(a),
Pi j k¯l¯(a) = λi (a)Ci (a)ui (a)(1 − (u j (a) + v j (a)))uk(a)ul(a),
Pi j¯ k¯l¯(a) = λi (a)Ci (a)ui (a)u j (a)uk(a)ul(a),
Pi jkl∗(a) = λi (a)Ci (a)ui (a)(1 − (u j (a) + v j (a)))(1 − (uk(a) + vk(a)))vl(a),
Pi jk∗l∗(a) = λi (a)Ci (a)ui (a)(1 − (u j (a) + v j (a)))vk(a)vl(a),
Pi j∗k∗l∗(a) = λi (a)Ci (a)ui (a)v j (a)vk(a)vl(a),
Pi jk∗ l¯(a) = λi (a)Ci (a)ui (a)(1 − (u j (a) + v j (a)))vk(a)ul(a),
Pi j∗k∗ l¯(a) = λi (a)Ci (a)ui (a)v j (a)vk(a)ul(a),
Pi j∗k¯l¯(a) = λi (a)Ci (a)ui (a)v j (a)uk(a)ul(a), (17)
where j , j∗, and j¯ indicate, respectively, a previous natural infection with serotype
j , successful vaccination against serotype j before age a, and no previous infection
with or vaccination against serotype j , that is, Pi jk∗ l¯(a) denotes the probability of
an infection with serotype i at age a after a previous infection with serotype j and
successful vaccination against serotype k but no exposure to serotype l. By denoting
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the corresponding risk functions in a similar manner, e.g. Ri jk∗ l¯(a), the expected risk
from an infection with serotype i at age a can then be calculated as
Ei (a) = Pi j¯ k¯l¯ (a)Ri j¯ k¯l¯ (a) + Pi j k¯l¯ (a)Ri j k¯l¯ (a) + Pi j¯kl¯ (a)Ri j¯kl¯ (a) + Pi j¯ k¯l (a)Ri j¯ k¯l (a)
+ Pi j∗k¯l¯ (a)Ri j∗k¯l¯ (a) + Pi j¯k∗ l¯ (a)Ri j¯k∗ l¯ (a) + Pi j¯ k¯l∗(a)Ri j¯ k¯l∗(a) + Pi jkl¯ (a)Ri jkl¯ (a)
+ Pi j k¯l (a)Ri j k¯l (a) + Pi j¯kl (a)Ri j¯kl (a) + Pi j∗k∗ l¯ (a)Ri j∗k∗ l¯ (a) + Pi j∗k¯l∗(a)Ri j∗k¯l∗(a)
+ Pi j¯k∗l∗(a)Ri j¯k∗l∗(a) + Pi jk∗ l¯ (a)Ri jk∗ l¯ (a) + Pi j k¯l∗(a)Ri j k¯l∗(a) + Pi j∗kl¯ (a)Ri j∗kl¯ (a)
+ Pi j∗k¯l (a)Ri j∗k¯l (a) + Pi j¯kl∗(a)Ri j¯kl∗(a) + Pi j¯k∗l (a)Ri j¯k∗l (a) + Pi jkl (a)Ri jkl (a)
+ Pi jkl∗(a)Ri jkl∗(a) + Pi jk∗l (a)Ri jk∗l (a) + Pi j∗kl (a)Ri j∗kl (a) + Pi jk∗l∗(a)Ri jk∗l∗(a)
+ Pi j∗kl∗(a)Ri j∗kl∗(a) + Pi j∗k∗l (a)Ri j∗k∗l (a) + Pi j∗k∗l∗(a)Ri j∗k∗l∗(a). (18)
The risks associated with the probabilities in Eq. (17) depend on several assumptions
and can be defined based on any negative effect an infection may have. The risk
functions are a measure of the undesirability of having dengue at a certain age, and
many definitions are possible. Considering that only a fraction of dengue cases lead
to severe symptoms while the majority show only mild symptoms or are completely
asymptomatic (Gubler 2011; Bhatt et al. 2013) the risk functions should be defined in
such a way that the burden of dengue is adequately described. We will consider the
risk of being admitted to hospital due to an infection. In this case the pre-vaccine risk
of hospitalisation can be derived from data provided by SINAN that was reviewed by
Burattini et al. (2016) to evaluate age differences in hospital admissions due to dengue.
The data show that the highest risk is associated with young ages, with a peak at
approximately 5.5 years. Adults have a relatively low risk of requiring hospitalisation,
but a significant increase in risk at ages above 70 years occurs. The risk function R(a)
describing the undesirability of acquiring dengue at age a in years based on the need
for hospital treatment can therefore be obtained by fitting a piecewise defined function
to the data. Based on the data the function at young ages is assumed to be of the form
k1ae−k2a and at older ages it is an exponential function of the type l1el2a . For ages
above the highest recorded age the risk is taken to be constant. The pre-vaccine risk
of hospitalisation is then given by:
R(a) =
⎧
⎪⎨
⎪⎩
0.09153ae−0.1820a, 0 ≤ a < 21.3333,
0.02428e0.02362a, 21.3333 ≤ a < 100,
0.02428e0.02362·100, 100 ≤ a < ∞.
(19)
If we assume that the risk of a secondary, tertiary, and quaternary infection does not
depend on whether the previous infections were natural infections or silent vaccine-
induced infections, then the associated risks can easily be defined depending on
whether ADE and permanent cross-immunity after two heterologous infections are
considered, that is, if there is ADE, we assume primary infections to be risk-free, i.e.
Ri j¯ k¯l¯(a) = 0 and all remaining infections to have the same risk which is approximated
by R(a). Similarly if there is no ADE and a secondary infection with a heterolo-
gous serotype confers permanent cross-immunity, we assume primary and secondary
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infections to have the same risk as before the introduction of the vaccine, and tertiary
and quaternary infections to be risk-free, i.e. Ri jkl(a) = Ri jkl¯(a) = Ri jkl∗(a) =
Ri jk∗l∗(a) = Ri j∗k∗l∗(a) = Ri jk∗ l¯(a) = Ri j∗k∗ l¯(a) = 0. However, results from the
long-term follow-up of Dengvaxia trials show an increased risk of hospitalisation in
seronegative vaccine recipients (SAGE/World Health Organization 2016; Martínez-
Vega et al. 2017; Aguiar and Stollenwerk 2017). Based on these results the associated
risk functions in the case of serostatus-dependent risk can be derived as outlined in
Supplementary Appendix B.
4.2 Lifetime Expected Risk E
Using the definition of the expected risk from an infection given by Eq. (18) we can
now define the lifetime expected risk E as the integral over the sum of the expected
risks of the different serotypes multiplied by the survival probability π(a) over all
ages, i.e. we define
E =
∫ ∞
0
( 4∑
i=1
Ei (a)
)
π(a)da. (20)
The incorporation of the survival probability is crucial since dengue does indeed
affect people of all ages and the consequences are very grave if infections occur at old
ages (Halstead 1980). This increased risk is often disregarded for infections that are
typically observed during childhood which leads to an underestimation of the lifetime
expected risk. On the other hand if the higher risk associated with an infection at old
ages is taken account of, the survival probability is neglected the risk is overestimated.
It is important to note that the inclusion of the survival probability in the lifetime
expected risk significantly reduces the risk in the case of a step death function, i.e.
due to the cut-off at L = 73.8 years the high risk above this age does not factor
in.
5 Steady-State Dynamics
In the previous section we introduced the lifetime expected risk of an infection with
dengue. The definition of this risk is based on the assumption that a steady-state
age distribution has been reached. We therefore need to find both the steady-state
age distributions and the steady-state force of infection for the human popula-
tion. At the steady state, the age distributions of the humans and the number of
mosquitoes in each compartment are constant in time. The age distributions of unaf-
fected, infected, and recovered humans are denoted by U (a) = limt→∞ UH (a, t),
I (a) = limt→∞ IH (a, t), and R(a) = limt→∞ RH (a, t), respectively. The steady-
state force of infection is denoted by λ(a) = limt→∞ λH (a, t).
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5.1 Steady-State Age Distribution
Consider the age distributions of the fractions of unaffected and infected humans at the
steady state with respect to the age distribution of all humans, i.e. u(a) = U (a)/N (a)
and i(a) = I (a)/N (a). At the steady state, with vaccination as previously described,
these fractions satisfy the ordinary differential equations
du
da
= −λ(a)C(a)u(a),
di
da
= λ(a)C(a)u(a) − γH i(a), (21)
with the initial conditions u(0) = 1 and i(0) = 0, and the matching condition
lim
a→A+i
u(a) = (1 − Vi C(Ai )) lim
a→A−i
u(a)
for each of the three vaccination ages.
This system can easily be solved to obtain
u(a) =
⎧
⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎩
e−
∫ a
0 λ(s)C(s)ds , 0 ≤ a < A1,
(1 − V1C(A1))e−
∫ a
0 λ(s)C(s)ds , A1 ≤ a < A2,
(1 − V1C(A1))(1 − V2C(A2))e−
∫ a
0 λ(s)C(s)ds , A2 ≤ a < A3,
(1 − V1C(A1))(1 − V2C(A2))(1 − V3C(A3))e−
∫ a
0 λ(s)C(s)ds , A3 ≤ a < ∞,
(22)
and
i(a) = e−γH a
∫ a
0
λ(s)C(s)u(s)eγH sds. (23)
Hence, the steady-state age distributions are U (a) = N (a)u(a) and I (a) = N (a)i(a).
5.2 Steady-State Force of Infection
The force of infection for the human population is given by Eq. (4). Considering that
at the steady state the number of infectious mosquitoes is given by IM this yields the
steady-state force of infection
λ(a) = lim
t→∞ λH (a, t) = q(a)
b
NH
IM . (24)
From the mosquito equations where the time derivatives are set to zero and by not-
ing SM = NM − (L M + IM ) we have λM SM = μM (L M + IM ) and μM IM =
e−μM τ λM SM where λM is the steady-state force of infection for the mosquito pop-
ulation. The number of infectious mosquitoes at the steady state is therefore given
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by IM = e−μM τ NM λMμM+λM . Using Eq. (5) with the steady-state age distribution
IH (a) = NHL i(a)π(a) for the infected humans and recalling m = NM/NH the steady-
state force of infection for humans is
λ(a) = q(a)mbe−μM τ
c
L
∫ ∞
0 q(a)i(a)π(a)da
μM + cL
∫ ∞
0 q(a)i(a)π(a)da
. (25)
We expect the steady-state force of infection to be different for each of the four
dengue serotypes. However, as mentioned in Sect. 3 the exact serotype-specific param-
eter values are not known. The steady-state force of infection can in fact be written in
terms of the basic reproduction number as given by Eq. (12). It is then given by
λ(a) = q(a)
4k32 (k2 + γH )2 (k2 − γH )2
4k32ωo + (k2 − γH )2 ((k2 + γH ) ω1 + k2ω2)
R0
∫ ∞
0 q(a)i(a)π(a)da
1 + c
μM L
∫ ∞
0 q(a)i(a)π(a)da
(26)
where ω0, ω1, and ω2 are given in Eq. (14). By solving this expression using the
serotype-specific basic reproduction numbers we found in Sect. 3.1 for a given vacci-
nation strategy one can compute the lifetime expected risk given by Eq. (20).
6 Results
We now want to find the optimal ages for vaccination against dengue with Dengvaxia
for any combination of serotypes in an endemic region by numerically evaluating the
lifetime expected risk derived in Sect. 4. This can be done by finding the serotype-
specific forces of infection as given by Eq. (26) where it is important to note that
since we assume independent transmission dynamics the combination of circulating
serotypes does not influence the force of infection for each of the serotypes present.
Most of the parameters needed for the computation of the steady-state force of
infections are already used in Sect. 3.1 to find the serotype-specific basic reproduction
numbers, and the same values are used for the computation of the lifetime expected
risk. The parameters that are still needed are the transmission probability from human
to mosquito c and the fractions Vi vaccinated at the ages Ai . For the probability of
transmission we take c = 1 from the literature (Massad et al. 2010) for all serotypes.
The vaccination ages Ai are such that the initial dose can be given at any age, while the
second and third dose is given according to the licence of Dengvaxia, i.e. A2 = A1 +6
months and A3 = A1 + 12 months. We do not restrict the initial age A1 to the age
range of the licence to find the optimal vaccination age. However, at the end of this
section we briefly compare the optimal age and lifetime expected risk to what can be
achieved under the current restrictions of the licence in Brazil, i.e. if vaccination takes
place between the ages of 9 and 45 years.
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Table 3 Vaccine efficacies as presented by Hadinegoro et al. (2015) and SAGE/World Health Organization
(2016)
Vaccine efficacy Age independent (%) Under 9 years (%) 9 years or older (%)
According to serotype
DENv1 54.7 46.6 58.4
DENv2 43.0 33.6 47.1
DENv3 71.6 62.1 73.6
DENv4 76.9 51.7 83.2
According to serostatus
Seropositive 78.2 70.1 81.9
Seronegative 38.1 14.4 52.5
The vaccinated fractions Vi are utilised to incorporate the vaccine efficacy of Deng-
vaxia for each serotype by setting Vi = 1−(1 − eff ) 13 where eff is the vaccine efficacy.
Two phase three trials (Capeding et al. 2014; Hadinegoro et al. 2015) have shown that
the efficacy depends on the serotype, the age of the recipient, and whether the recipient
had a prior dengue infection or not. A summary of the different vaccine efficacies is
given in Table 3. However, there is some dispute about the age dependence of the vac-
cine with some researchers, arguing that the increase in efficacy for older recipients
is mainly due to the serostatus of the recipient (Halstead and Aguiar 2016; Halstead
2016; Aguiar et al. 2016; Flasche et al. 2016). The data from the long-term follow-up of
the trials further indicate an increased risk of hospitalisation in seronegative recipients
(Martínez-Vega et al. 2017; Aguiar et al. 2016). In addition to the constant, serotype-
specific vaccine efficacy we will therefore consider vaccine-induced hospitalisation
risk, as well as the effect of an age-dependent, serotype-specific vaccine efficacy.
As mentioned in introduction, there is significant evidence that mainly secondary,
heterologous infections are responsible for SD while primary infections are often
asymptomatic. It is also believed that a secondary infection with a heterologous
serotype confers permanent cross-immunity to all serotypes or at least that tertiary
and quaternary infections are asymptomatic (Gibbons et al. 2007; Anderson et al.
2013). ADE and cross-immunity after two heterologous infections therefore impact
the lifetime expected risk in addition to the vaccine efficacy and whether the risk is
serostatus dependent. We therefore present results comparing the effect of assuming
risky and risk-free primary infections, as well as symptomatic and asymptomatic third
and fourth infections after two heterologous infections. Note that the tetravalence of
the vaccine leads to the possibility of secondary, tertiary, and quaternary infections
even if not all four serotypes coexist since the successful vaccination against any
serotype can be considered a silent infection.
6.1 Constant Efficacy
Table 4 shows the obtained optimal vaccination age (in other words the optimal age of
the first vaccination) and the corresponding minimal lifetime expected risk of a constant
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(a) The optimal vaccination age A1 for DENv1, 2, 3 and
4 is 14, 9, 14, and 23 months for risky primary infections
(top). For risk-free primary infections vaccination is not rec-
ommended.
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(b) The optimal vaccination age A1 for DENv1, 2, 3 and
4 is 13, 14, 14, and 17 months for risky primary infections
(top). For risk-free primary infections vaccination is not rec-
ommended.
Fig. 2 Lifetime expected risk E in an endemic area with a single serotype as a function of age A1 in months
at which the first of three doses of vaccine is administered for constant efficacy as given in Table 3 where
third and fourth infections are assumed a symptomatic, and b asymptomatic. The graphs at the top show
results for risky primary infections, while those at the bottom show results for risk-free primary infections.
The risk associated with an infection is based on hospitalisation as given by Eq. (19)
vaccine efficacy for all possible combinations of serotypes coexisting when vaccina-
tion aims at reducing the risk of hospitalisation without serostatus-dependent risk and
of hospitalisation with serostatus-dependent risk. The optimal vaccination ages are
very low if the vaccine is not assumed to increase the risk in seronegative recipients,
independent of the number of serotypes, and any other assumptions. The only excep-
tion to this is if primary infections are assumed risk-free when only one serotype exists;
in this case vaccination is not recommended. In the case of serostatus-dependent risk
vaccination ages vary much more and depend significantly on whether third and fourth
infections are asymptomatic or not. If primary infections are considered to be risk-free,
vaccination is again not recommended for only one serotype. In addition vaccination
is also not recommended for some scenarios with a single serotype in existence and
risky primary infection. The assumption of ADE leads to a slight increase in optimal
vaccination age for symptomatic third and fourth infections, but has no effect on the
optimal vaccination age in the case of permanent cross-immunity.
We will begin by discussing in detail the results for constant efficacy when the
risk does not depend on the serostatus of the recipient. For the different combinations
of one, two, three, and four co-circulating serotypes the lifetime expected risks are
shown in Figs. 2, 3, 4 and 5, respectively. For each combination of serotypes the
figures present four different graphs, subfigure a shows results for symptomatic post-
secondary infections, while subfigure b shows those for asymptomatic post-secondary
infections. The top graph in both subfigures a and b considers risky primary infections,
and the bottom graph risk-free primary infections. In each case the lifetime expected
risk E is plotted against the vaccination age A1 in months at which the first dose is
administered. Since the goal is to minimise this risk the optimal vaccination age is the
age A1 with the lowest lifetime expected risk E . Note that in Figs. 2, 3, 4 and 5 the
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(a) The optimal vaccination age A1 for DENv12, DENv13,
DENv14, DENv23, DENv24, and DENv34 is 11, 14, 18, 14,
17, and 17 months for risky primary infections (top) and 76,
58, 63, 70, 70, and 48 months for risk-free primary infections
(bottom) respectively.
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(b) The optimal vaccination age A1 for DENv12, DENv13,
DENv14, DENv23, DENv24, and DENv34 is 11, 12, 13, 12,
14, and 14 months for risky primary infections (top) and 28,
28, 28, 28, 35, and 28 months for risk-free primary infections
(bottom) respectively.
Fig. 3 Lifetime expected risk E in an endemic area with two coexisting serotypes as a function of age
A1 in months at which the first of three doses of vaccine is administered for constant efficacy as given in
Table 3 where third and fourth infections are assumed a symptomatic and b asymptomatic. The graphs
at the top show results for risky primary infections, while those at the bottom show results for risk-free
primary infections. The risk associated with an infection is based on hospitalisation as given by Eq. (19)
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(a) The optimal vaccination age A1 for DENv123, DENv124,
DENv134, and DENv234 is 14, 17, 17, and 17 months for
risky primary infections (top) and 48, 48, 42, and 48 months
for risk-free primary infections (bottom) respectively.
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(b)The optimal vaccination age A1 for DENv123, DENv124,
DENv134, and DENv234 is 11 months for risky primary infec-
tions (top) and 21, 24, 24, and 24 months for risk-free primary
infections (bottom) respectively.
Fig. 4 Lifetime expected risk E in an endemic area with three coexisting serotypes as a function of age
A1 in months at which the first of three doses of vaccine is administered a for symptomatic and b for
asymptomatic tertiary infections. The graphs at the top show results for risky primary infections, while
those at the bottom show results for risk-free primary infections. The risk associated with an infection is
based on hospitalisation as given by Eq. (19)
results shown on the left of Table 4 are presented, i.e. the vaccine efficacy is constant
and only depends on the serotype, while the hospitalisation risk only depends on the
age at infection but not the serostatus.
While in most endemic areas there are several coexisting serotypes, considering
the case of a single serotype allows us to draw conclusions about the different vac-
cine efficacies and basic reproduction numbers. We therefore start by considering an
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(a) The optimal vaccination age A1 for DENv1234 is 17
months for risky primary infections (top) and 38 months for
risk-free primary infections (bottom) respectively.
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(b) The optimal vaccination age A1 for DENv1234 is 10
months for risky primary infections (top) and 21 months for
risk-free primary infections (bottom) respectively.
Fig. 5 Lifetime expected risk E in an endemic area with all serotypes co-circulating as a function of
age A1 in months at which the first of three doses of vaccine is administered a for symptomatic and b
for asymptomatic tertiary and quaternary infections. The graphs at the top show results for risky primary
infections, while those at the bottom show results for risk-free primary infections. The risk associated with
an infection is based on hospitalisation as given by Eq. (19)
endemic area where only a single serotype is present. The corresponding results are
presented in Fig. 2. Vaccination is assumed to cause a silent infection if it is successful,
so that due to the tetravalence of the vaccine secondary, tertiary, and quaternary infec-
tions are possible even if only one serotype circulates. If all infections are assumed
equally risky, as shown in the top graph in Fig. 2a, the minimal lifetime expected risk
is found at very young ages between 9 and 22 months for any of the serotypes. It
can further be seen that for young vaccination ages the lifetime expected risk due to
DENv4 is the lowest, followed by DENv3, DENv1, and lastly DENv2. On the other
hand if vaccination is initiated at approximately 11.5 years or later, DENv2 causes
the lowest lifetime expected risk. These observations can be explained by considering
the serotype-specific basic reproduction numbers and vaccine efficacies as given in
Tables 2 and 3. At young ages an effective vaccine can prevent a considerable num-
ber of cases even if the basic reproduction number is high so that the high vaccine
efficacies for DENv3 and 4 (71.6% and 76.9%, respectively) lead to a low lifetime
expected risk. On the other hand the lower efficacies for DENv1 and 2 with 54.7%
and 43.0%, respectively, imply that even if vaccination occurs early, not many infec-
tions are prevented. The lifetime expected risk is therefore still fairly high and in fact
highest for DENv2 even though it has the lowest basic reproduction number. If vac-
cination is given only to individuals aged 11.5 years or older, many infections will
have already occurred, particularly if the basic reproduction number is high as is the
case for serotypes 1, 3, and 4, so that vaccination will not reduce the overall risk. For
DENv2 the basic reproduction number is significantly lower than for the remaining
serotypes so that some cases in later life can be prevented even with the lower vaccine
efficacy thus resulting in the lifetime expected risk due to DENv2 being the lowest at
these high vaccination ages.
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However, if we consider the first infection to be risk-free, we can see that the lifetime
expected risk decreases with vaccination age for all serotypes. DENv2 always poses the
highest risk due to the low efficacy for this serotype. With a step death function it makes
sense to consider vaccination only within the age range 0–L years, where L = 73.8
years is the maximum human lifetime. Therefore, vaccination is not recommended if
only one serotype exists but immunity caused by natural infection or vaccination leads
to ADE. This can also intuitively be concluded, since if there is only one serotype,
but primary infections are risk-free, there is no need to vaccinate at all. Now if instead
of assuming symptomatic third and fourth infections we assume secondary infections
to confer permanent cross-immunity, the corresponding results are shown in Fig. 2b.
While the overall conclusions are very similar to the symptomatic case the lifetime
expected risk is lower in general since a natural infection that occurs after successful
vaccination against two other serotypes now no longer contributes to the lifetime
expected risk. The optimal vaccination age decreases slightly to between 13 and 17
months in the case of risky primary infections. In this case it is particularly noticeable
that the effects of the differences in basic reproduction number and efficacy of the
serotypes are less pronounced if there is permanent cross-immunity. This is due to
the fact that independent of circulating serotype successful vaccination against two
serotypes means the natural infection will not be risky. For risk-free primary infections
vaccination is again not recommended.
We now consider an endemic area with two co-circulating serotypes. The results are
presented in Fig. 3. We shall start by considering all infections to be equally risky, i.e.
the results presented in the graph at the top of Fig. 3a. We can see that similarly to one
serotype existing very low vaccination ages are obtained which lie between 11 and 18
months. The effect of the vaccine efficacy is also similar to the case of a single serotype
since the low efficacy of DENv2 leads to a higher lifetime expected risk whenever
this serotype is present at young vaccination ages, while the combination of DENv3
and 4 leads to the lowest lifetime expected risk due the high combined efficacy. These
observations are to be expected after considering the single serotype scenario and also
apply in the case of risk-free primary infections as can be seen in the bottom graph.
Assuming risk-free primary infections, however, leads to a lower lifetime expected
risk and an optimal vaccination age between 48 and 76 months, i.e. much higher
than for risky primary infections. The decrease in lifetime expected risk is caused by
primary infections not contributing to the risk. The increase in vaccination age is due
to fewer potentially risky infections at young ages, so that it is better to vaccinate
later when maternal antibodies have declined. Comparing the lifetime expected risk
of risky and risk-free primary infections shows that for risk-free primary infections
there is a slightly wider range in which near optimal vaccination is possible.
Next we shall assume instead that tertiary and quaternary infections are asymp-
tomatic, i.e. risk-free, as shown in Fig. 3b. As was the case for a single serotype it can
immediately be seen that different efficacies and basic reproduction numbers have less
effect in this case. Also the effect of assuming risk-free primary infections as opposed
to risky ones becomes more pronounced, with a much wider range in which vaccina-
tion is near optimal in the former case and an increase in the optimal vaccination age
from between 11 and 14 months to between 28 and 35 months. It can therefore be noted
that assuming risk-free primary infections in general increases the optimal vaccination
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age, while assuming asymptomatic, i.e. risk-free, tertiary, and quaternary, infections
decreases the optimal age particularly if primary infections are considered risk-free.
For risk-free primary infections the optimal age increases since the first infection does
not need to be prevented; in fact, if vaccination is only successful against one serotype,
it is better to wait. On the other hand if third and fourth infections are asymptomatic
vaccinating after a secondary infection will be useless so that in this case the optimal
ages decrease.
We now increase the number of serotypes in an endemic area to three. The results
for this scenario are presented in Fig. 4. Again we start by assuming that all infections
are equally risky, i.e. symptomatic; then, from the top of Fig. 4a we can see that the
optimal vaccination ages are between 14 and 17 months which is similar to the cases
of one or two coexisting serotypes. Again it can be seen that for low vaccination ages
the combination of DENv1, 3, and 4 has the lowest lifetime expected risk since this
combination has the highest combined efficacy, and the combination of DENv1, 2,
and 3 leads to the highest lifetime expected risk since the combined efficacy is lowest.
Therefore, the same observations are made as for one or two coexisting serotypes.
This is also true with respect to risk-free primary infections and symptomatic third
and fourth infections as shown at the bottom of Fig. 4a. Again the optimal vaccination
ages increase to between 42 and 48 months, and there is a wider range in which near
optimal vaccination is possible for the reasons previously discussed. For asymptomatic
third and fourth infections as shown in Fig. 4b the vaccination ages are 11 months
for risky primary infections and between 21 and 24 months for risk-free primary
infections. Again the graphs clearly show that the differences in efficacy and basic
reproduction number are less decisive for the lifetime expected risk than in the case of
symptomatic tertiary and quaternary infections. Similar to the case of two coexisting
serotypes it can also be seen that the age range in which near optimal vaccination is
possible increases more significantly for asymptomatic third and fourth infections if
risk-free primary infections are considered than in the case of symptomatic ones.
Finally consider an endemic area with all four dengue serotypes DENv1–4 coex-
isting. The results for this case are presented in Fig. 5. The optimal vaccination age
obtained for symptomatic tertiary and quaternary infections is 17 months in the case of
risky primary infections and 38 months for risk-free ones. For asymptomatic third and
fourth infections the corresponding optimal vaccination ages are 10 and 21 months.
The lifetime expected risk is lower for risk-free primary infections as was the case for
less co-circulating serotypes. The assumption of risk-free primary infections leads to
a higher optimal vaccination age than for risky primary infection with a wider range in
which near optimal vaccination is possible, and assuming permanent cross-immunity
after two heterologous infections results in a significant decrease in optimal vaccina-
tion age. The results for four serotypes are therefore as expected from considering less
coexisting serotypes.
6.2 Serostatus-Dependent Risk
One of the most challenging aspects of dengue vaccination is the potential for an
increased risk caused by the vaccine itself. From the long-term follow-up of the Deng-
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(a) The optimal vaccination age A1 for DENv1234 is 77
months for risky primary infections (top) and 91 months for
risk-free primary infections (bottom) respectively.
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(b) The optimal vaccination age A1 for DENv1234 is 156
months both for risky primary infections (top) and for risk-
free primary infections (bottom).
Fig. 6 Lifetime expected risk E in an endemic area with all serotypes co-circulating as a function of
age A1 in months at which the first of three doses of vaccine is administered a for symptomatic and b
for asymptomatic tertiary and quaternary infections. The graphs at the top show results for risky primary
infections, while those at the bottom show results for risk-free primary infections. The risk associated with
an infection is based on hospitalisation as given by Eq. (19). Additionally vaccination induces an increased
risk in seronegative recipients according to Table B.1 (see Supplementary Appendix B)
vaxia trials it has been shown that initially seronegative recipients may experience a
higher risk of hospitalisation in breakthrough cases after vaccination (SAGE/World
Health Organization 2016; Martínez-Vega et al. 2017; Aguiar et al. 2016). Based on
the data from these trials we therefore consider serostatus-dependent hospitalisation
risk by determining the risk functions which we defined in Sect. 4 as described in Sup-
plementary Appendix B. The minimal lifetime expected risk and optimal vaccination
age for any number and combination of serotypes and for the different assumptions
relating to ADE and cross-immunity are presented on the right of Table 4. Note that
the vaccine efficacy used in the matching conditions is still assumed constant and
only depends on the serotype, while the hospitalisation risk now depends on both
the age at infection and the serostatus just prior to infection. In the case of serostatus-
dependent risk, vaccination of an individual who was initially seronegative is generally
not desirable unless they are successfully vaccinated against all endemic serotypes. It
is therefore not surprising that the optimal vaccination age increases, so as to vaccinate
less seronegatives compared to the case of no serostatus-dependent risk. However, if
two heterologous infections confer permanent cross-immunity, it can still be bene-
ficial to vaccinate seronegatives if they are successfully vaccinated against at least
two serotypes since subsequent natural infections will be asymptomatic. For risk-free
primary infections but symptomatic third and fourth infections it is least desirable to
vaccinate seronegatives because successful vaccination against less than four serotypes
will increase their risk in every breakthrough natural infection.
We will briefly consider the consequences of a serostatus-dependent risk on the
basis of all four serotypes coexisting as shown in Fig. 6.
By comparing Figs. 5 and 6 we can see that serostatus-dependent risk has a sig-
nificant effect on the lifetime expected risk. Particularly at young ages, vaccination
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with a vaccine that induces an additional risk in seronegative recipients leads to a
higher lifetime expected risk. Once the vaccination age increases to ages in which few
individuals are seronegative the effect is much less pronounced. The optimal vacci-
nation ages independent of the assumptions to ADE and permanent cross-immunity
are therefore higher with a vaccine-induced risk. For symptomatic third and fourth
infections it can further be seen that the optimal vaccination age increases slightly
if primary infections are assumed risk-free. If post-secondary infections are asymp-
tomatic, there is hardly any difference between risky and risk-free primary infections.
In this case vaccinating at early ages increases the lifetime expected risk significantly
independent of whether ADE is considered or not. Independent of whether primary
infections are risky or not it is therefore ideal to vaccinate after the first natural infec-
tion occurred if post-secondary infections are asymptomatic. This has two reasons:
Firstly, seropositive individuals are not exposed to an increased risk by vaccination so
that it is better to wait for more individuals to have had a natural infection. Secondly,
if a seropositive individual is successfully vaccinated against any serotype, they were
not infected with permanent cross-immunity and will protect them against all future
infections. From Fig. 6b it can be seen that the optimal vaccination age is 13 years for
permanent cross-immunity independent of the assumption relating to ADE; 13 years
is therefore the age at which most primary infections but few secondary infections
will have occurred.
6.3 Age-Dependent Vaccine Efficacy
So far only results for constant vaccine efficacies were presented. However, as men-
tioned before, Hadinegoro et al. (2015) found the vaccine efficacies to increase for
recipients aged 9 years or older. This phenomenon is believed to be caused by the
serostatus of the recipient rather than their age and the constant efficacy can therefore
be considered to be more accurate. Additionally, if the vaccine does not induce a higher
risk in seronegative recipients, the optimal ages in the case of age-dependent vaccine
efficacy are in fact very similar to those presented in Table 4 for constant vaccine
efficacy. We will therefore only briefly highlight the differences between constant and
age-dependent vaccine efficacy results by considering a single serotype in existence
and no serostatus-dependent risk.
If the vaccine efficacy for the serotypes is based on the age groups as given in
Table 3 the resulting lifetime expected risk of a single serotype is shown in Fig. 7.
For all serotypes the efficacy based on age groups is lower for children under the age
of 9 years and higher for individuals aged 9 years or older in comparison with the
constant efficacies. While the observations of the constant efficacy case also apply to
the age-dependent case, the increase in efficacy for any of the three vaccination doses
leads to a drop in lifetime expected risk which can be seen at ages A1 ∈ {96, 102, 108}
months. The drops are more pronounced in the case of risky primary infections both
for symptomatic and for asymptomatic third and fourth infections. Despite the highest
efficacy being reached once all three doses are given above the age of 9 years, i.e. once
A1 ≥ 108 months, the optimal vaccination ages remain very low for risky primary
infections independent of the symptomaticity of tertiary and quaternary infections.
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(a) The optimal vaccination age A1 for DENv1, 2, 3 and
4 is 14, 9, 14, and 22 months for risky primary infections
(top). For risk-free primary infections vaccination is not rec-
ommended.
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(b) The optimal vaccination age A1 for DENv1, 2, 3 and
4 is 14, 14, 14, and 17 months for risky primary infections
(top). For risk-free primary infections vaccination is not rec-
ommended.
Fig. 7 Lifetime expected risk E in an endemic area with a single serotype as a function of age A1 in months
at which the first of three doses of vaccine is administered for vaccine efficacy depending on the age groups
< 9 and ≥ 9 years as shown in Table 3 where third and fourth infections are assumed a symptomatic and
b asymptomatic. The graphs at the top show results for risky primary infections, while those at the bottom
show results for risk-free primary infections. The risk associated with an infection is based on hospitalisation
as given by Eq. (19)
In fact they differ by no more than 1 month from the constant efficacy case. The
lower vaccine efficacy in under 9 years old is also responsible for the higher lifetime
expected risk in this age-group in comparison with the constant efficacy results. For
risk-free primary infections vaccination is again not recommended. Similar effects
can be observed for more than one serotype in circulation. However, it is important
to note that the increase in efficacy at 9 years has a significant impact on the optimal
vaccination ages in the case of two serotypes coexisting when primary infections are
risk-free and post-secondary infections are symptomatic. The reason for this is that
the optimal vaccination ages for constant efficacy in this case are already fairly high
as shown in Table 4; the increased efficacy at 9 years decreases the lifetime expected
risk sufficiently to lead to a higher optimal vaccination age of exactly 9 years for most
combinations of two serotypes.
6.4 Licence Restrictions
The current licence of Dengvaxia only allows vaccination of individuals aged between
9 and 45 years in Brazil. However, when vaccination does not induce an additional risk
the optimal vaccination age for the risk of hospitalisation lies between 9 and 76 months
for almost any scenario as shown in Table 4. The only exception is one circulating
serotype and risk-free primary infections in which case the optimal vaccination policy
was not to vaccinate. The optimal vaccination ages are therefore significantly below the
permitted age range if there is no serostatus-dependent risk. In the case of serostatus-
dependent risk only very few optimal vaccination ages are below 9 years. However,
the optimal vaccination ages in this case are much closer to the permitted age range
than when the vaccine is not assumed to induce any additional risk. If the age at which
123
The Optimal Age of Vaccination Against Dengue… Page 27 of 32    12 
the first dose of the vaccine can be administered is restricted such that all doses are
given to individuals aged 9–45 years, the optimal vaccination age is 108 months in all
cases in which vaccination is recommended independent of the assumption regarding
the serostatus-dependent risk. However, restricting the vaccination age as required by
the licence leads to a significant increase in lifetime expected risk compared to what
could be achieved if vaccination was possible at younger ages. For cases in which
vaccination is recommended the increase in the lifetime expected risk compared to
its optimum as given in Table 4 lies between approximately 7% and 630% without a
vaccine-induced risk and below 7% when such a risk is considered. The percentage
increase is higher the further from the optimal age vaccination takes place under the
age restriction.
7 Discussion
In this paper we found the optimal vaccination age for dengue vaccination in Brazil
according to a routine vaccination calendar in endemic regions with any number and
combination of dengue serotypes. We assumed independent transmission dynamics
for the different serotypes and derived both an exact and an approximate expression
for the basic reproduction number of our model. From data we then found serotype-
specific basic reproduction numbers, an age-dependent mosquito biting rate, and an
age-dependent risk function describing the undesirability of getting an infection in
terms of the risk of hospitalisation. The vaccine efficacy in the transmission model was
assumed serotype specific, results corresponding to constant efficacy were presented
in detail while those corresponding to age-dependent efficacy were presented only for
the risk of hospitalisation in an area with one serotype and briefly addressed otherwise.
In addition we discussed the effect of an increased risk in seronegative recipients. Risk-
free primary infections corresponding to ADE and permanent cross-protection after
two heterologous infections were considered. For optimal vaccination ages that did
not match the current age range of 9–45 years for which Dengvaxia can be used in
Brazil we further determined the optimal vaccination age under these constraints.
The optimal vaccination ages which we obtained for constant efficacy in the case of
hospitalisation and hospitalisation with a serostatus-dependent risk are given in Table 4
alongside the minimal lifetime expected risk. We found that optimal vaccination ages
if there is no serostatus-dependent risk are very low. For risky primary infections the
optimal age is between 9 and 23 months, while for risk-free primary infections it is
between 21 and 76 months when vaccination is recommended. The increase in optimal
vaccination age if primary infections are considered risk-free can be explained by
considering that in this case vaccination is beneficial only after a primary but before
a secondary infection. On the one hand this is because at younger ages it may be
given to children who are still protected by maternal antibodies and will thus not be
effective. On the other hand if vaccination is successful only against one serotype,
the first natural infection will correspond to a secondary infection and thus result in a
higher risk. This is also the reason why vaccination is not recommended if only a single
serotype is in circulation and primary infections are risk-free, i.e. dengue infections are
subject to ADE. The assumption of asymptomatic tertiary and quaternary infections,
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i.e. secondary infections effectively conferring permanent cross-immunity, resulted
in lower optimal vaccination ages than those found for corresponding results with
symptomatic infections. This change is larger when the assumption is that primary
infections are risk-free since in this case vaccination is only beneficial if it prevents
secondary infections.
Dengvaxia was first licensed in December 2015. Since the introduction of Deng-
vaxia in endemic countries concerns about its application in seronegative recipients
have been raised due to an increase in SD cases in those recipients, and the need for
pre-vaccination screening has been discussed (Halstead and Aguiar 2016; Halstead
2016; Aguiar et al. 2016; Flasche et al. 2016). Considering the increased hospitalisa-
tion risk in seronegative recipients that was observed in the long-term follow-up of
Dengvaxia trials (SAGE/World Health Organization 2016; Martínez-Vega et al. 2017;
Aguiar et al. 2016), we considered serostatus-dependent risk by calculating relative
risks according to serostatus as described in Supplementary Appendix B. The optimal
vaccination ages and lifetime expected risks are presented in Table 4. With an imper-
fect vaccine and an increased risk in breakthrough infections of initially seronegative
recipients it can be counterproductive to vaccinate seronegative recipients. It is there-
fore not surprising that in the case of serostatus-dependent risk the optimal vaccination
ages were found to be much higher in every case. This is due to the fact that ideally
vaccination takes place after most primary infections occurred to prevent exposing
vaccinated individuals to any additional risk. More circulating serotypes generally
reduce the average age of a primary infection; therefore, the optimal vaccination age
decreases slightly as the number of serotypes increases. Considering that vaccination
is already carried out at an age at which few individuals are seropositive it is not sur-
prising that the assumption of ADE has little effect on the optimal vaccination age.
Most of the obtained optimal vaccination ages in the case of a serostatus-dependent
risk are in the permitted age range of Dengvaxia. Again, for risk-free primary infec-
tions and only a single serotype in existence it is best not to vaccinate. In addition
some combinations of a single serotype in existence with risky primary infections are
also better not targeted by vaccination.
The vaccine efficacy of Dengvaxia was found to be age dependent in several Phase
Three trials (Capeding et al. 2014; Hadinegoro et al. 2015), and we therefore repeated
all simulations using the age-dependent efficacies and presented the results for cases
with one serotype and no serostatus-dependent risk. For the remaining cases the results
were briefly discussed. The optimal vaccination ages are found to be very similar to
those presented in Table 4 with the exceptions of most combinations of two coexisting
serotypes if primary infections are risk-free and tertiary and quaternary infections
symptomatic. In these cases the optimal vaccination age was found to be 108 months,
i.e. 9 years. These are in fact the only scenarios for which we found the optimal
vaccination age to be in the age range for which Dengvaxia is licensed in Brazil if
there is no serostatus-dependent risk.
If the vaccination age is restricted to between the ages of 9 and 45 years, the optimal
vaccination age is 108 months for all cases in which vaccination is recommended,
irrespective of all other assumptions. This vaccination age is the earliest possible age
at which vaccination is permitted under the licence restrictions and thus as soon as
possible after the actual optimal vaccination age. The lifetime expected risk at this
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age is significantly higher than at the optimum. In general the later vaccination can
take place after the optimal vaccination age the higher the percentage increase from
the minimal lifetime expected risk is.
The most likely scenario in the majority of endemic areas in Brazil, and in fact in
the world, is that all four dengue serotypes coexist. Based on the evaluation of nearly 7
million cases leading to hospitalisation in Brazil (Burattini et al. 2016) our conclusion
is that primary infections are in fact risky. This does not mean that ADE does not play
an important role in the risk of dengue, but there is a trade-off between the probability
that secondary infections are more risky than primary ones and reducing the risk of
getting a secondary infection. Therefore, results considering risky primary infections
may be more relevant. Since third and fourth infections are rarely reported (Fried
et al. 2010; Gibbons et al. 2007) it seems reasonable to assume asymptomatic third
and fourth infections. We will therefore briefly discuss the optimal vaccination ages
we obtained in the case of all four serotypes coexisting when primary infections are
considered risky, and third and fourth infections asymptomatic. Assuming a constant
efficacy the optimal vaccination age was found to be 10 months. This is, however,
significantly below the licensed age range of 9–45 years for Dengvaxia. If vaccination
is only possible within this age range, it should be carried out at 108 months which will
lead to an increase in lifetime expected risk of roughly 620%. If the vaccine increases
the risk in seronegative recipients, the optimal vaccination age was found to be 156
months, i.e. 13 years, and therefore within the permitted age range.
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